Coelenterazine-Utilizing Luciferase Reporters with Extremely Stable Glow-Type Bioluminescent Signal

Technology description

The name of the technology: Coelenterazine-Utilizing Luciferase Reporters with Extremely Stable Glow-Type Bioluminescent Signal
Challenge: Luminescence reporters are useful and popular tools in research and biotechnologies, allowing easy-to-use, rapid, safe, and sensitive monitoring of biological, biochemical, and chemical processes by measuring an optical signal. The luminescence process is initiated by the excitation of luminescent molecules to a high-energy state. Return to the ground state with lower energy is accompanied by the release of a photon, observable as light emission.

Bioluminescence is a fascinating phenomenon involving the emission of light by a living creature. There is enormous interest in harnessing bioluminescent systems to design ultrasensitive optical bioassays.

Despite many advances and improvements in luciferases, two major limitations are preserved. I. the flash-type of the signal with a short half-life prevents prolonged signal collection and analyses. II. moderate substrate affinity does not allow analyses at lower substrate concentrations with the maintained level of the detected signal.
Description: The present invention relates to modified protein sequences of coelenterazine-utilizing Renilla-type luciferases utilizing widely accessible, non-cytotoxic, and low-cost coelenterazine luciferin. These novel luciferases exhibit extremely stable glow-type light emission, high substrate affinity, low product inhibition factor, and modulated emission maximum. The luciferases are designed to provide ultrasensitive and stable bioluminescent signals in a wide range of laboratory applications and bioassay formats.
- extremely stable glow-type bioluminescent signal
- high affinity towards luciferin substrate
- low product inhibition
- enhanced thermostability
- high resistance to inactivation
- high expressibility & solubility
- no cytotoxicity
- tunable light emission enabling multiplexing
- highly compliant to crystalize & high diffraction quality.
- wide range of biosensor and reporter applications and bioassay formats
- in vitro and in vivo bioimaging applications
- long-term bioimaging with stable bioluminescent signal
- suitable for bioluminescence resonance energy transfer (BRET) technologies
- codon-optimized gene reporters for both bacterial and mammalian expression
- his-tagged luciferases enabling affinity purification & immunodetection
- recombinantly-produced and purified luciferases ready for use.
Commercial opportunity: The improved detection system is intended for all those who work with reporter asays for monitoring the expression of specific genes.
IP protection status: PCT application filed.
Development status:

Phase 2

Corresponds with TRL 3 and TRL 4

Feasibility study. There is a realistic design of the technology and the initial tests in the laboratory are leading to the specification of the technology requirements and its capabilities.

  • TRL 3 represents a complete idea of a technology with the design of concrete steps, tests and experiments that will need to be carried out to verify that the idea is realistic
  • TRL 4 is a verification of functionality in the laboratory. The result of TRL 4 is the so-called Proof-of-Concept. Technology is therefore designed and tested for its functionality under limited conditions
Partnering strategy: Collaboration licensing
More information: The University is looking for a commercial partner who would develop the technology into a commercial product – as a kit for in vitro and in vivo bioimaging.
The technology is also available for licensing.
Categories: Research Tools Chemistry Chemical and bioengineering
Owner of a technology: Masarykova univerzita
Back to list


Are you interested about this technology?

For more information about the project, please fill in this online form. The owner of the project will receive your enquiry.